176 related articles for article (PubMed ID: 36476479)
1. Inhibition of bone erosion, determined by high-resolution peripheral quantitative computed tomography (HR-pQCT), in rheumatoid arthritis patients receiving a conventional synthetic disease-modifying anti-rheumatic drug (csDMARD) plus denosumab vs csDMARD therapy alone: an open-label, randomized, parallel-group study.
Iwamoto N; Chiba K; Sato S; Shiraishi K; Watanabe K; Oki N; Okada A; Koga T; Kawashiri SY; Tamai M; Hosogaya N; Furuyama M; Kobayashi M; Saito K; Okubo N; Uetani M; Osaki M; Kawakami A
Arthritis Res Ther; 2022 Dec; 24(1):264. PubMed ID: 36476479
[TBL] [Abstract][Full Text] [Related]
2. Comparative study of the inhibitory effect on bone erosion progression with denosumab treatment and conventional treatment in rheumatoid arthritis patients: study protocol for an open-label randomized controlled trial by HR-pQCT.
Iwamoto N; Sato S; Sumiyoshi R; Chiba K; Miyamoto N; Arinaga K; Kobayashi M; Yamamoto H; Osaki M; Kawakami A
Trials; 2019 Aug; 20(1):494. PubMed ID: 31409388
[TBL] [Abstract][Full Text] [Related]
3. Denosumab improves bone mineral density and microarchitecture in rheumatoid arthritis: randomized controlled trial by HR-pQCT.
Chiba K; Iwamoto N; Watanabe K; Shiraishi K; Saito K; Okubo N; Kawakami A; Osaki M
J Bone Miner Metab; 2023 Nov; 41(6):797-806. PubMed ID: 37480398
[TBL] [Abstract][Full Text] [Related]
4. Effects of RANKL inhibition on promoting healing of bone erosion in rheumatoid arthritis using HR-pQCT: a 2-year, randomised, double-blind, placebo-controlled trial.
So H; Cheng IT; Lau SL; Chow E; Lam T; Hung VW; Li EK; Griffith JF; Lee VW; Shi L; Huang J; Kwok KY; Yim CW; Li TK; Lo V; Lee J; Lee JJ; Qin L; Tam LS
Ann Rheum Dis; 2021 Aug; 80(8):981-988. PubMed ID: 33811034
[TBL] [Abstract][Full Text] [Related]
5. Association of denosumab with serum cytokines, chemokines, and bone-related factors in patients with rheumatoid arthritis: A post hoc analysis of a multicentre, open-label, randomised, parallel-group study.
Iwamoto N; Sato S; Furukawa K; Michitsuji T; Shiraishi K; Watanabe K; Chiba K; Osaki M; Kawakami A
Mod Rheumatol; 2024 Jan; ():. PubMed ID: 38226481
[TBL] [Abstract][Full Text] [Related]
6. Effects of the anti-RANKL antibody denosumab on joint structural damage in patients with rheumatoid arthritis treated with conventional synthetic disease-modifying antirheumatic drugs (DESIRABLE study): a randomised, double-blind, placebo-controlled phase 3 trial.
Takeuchi T; Tanaka Y; Soen S; Yamanaka H; Yoneda T; Tanaka S; Nitta T; Okubo N; Genant HK; van der Heijde D
Ann Rheum Dis; 2019 Jul; 78(7):899-907. PubMed ID: 31036625
[TBL] [Abstract][Full Text] [Related]
7. Assessment of 3-month changes in bone microstructure under anti-TNFα therapy in patients with rheumatoid arthritis using high-resolution peripheral quantitative computed tomography (HR-pQCT).
Shimizu T; Choi HJ; Heilmeier U; Tanaka M; Burghardt AJ; Gong J; Chanchek N; Link TM; Graf J; Imboden JB; Li X
Arthritis Res Ther; 2017 Oct; 19(1):222. PubMed ID: 28978352
[TBL] [Abstract][Full Text] [Related]
8. Effect of Half-Dose vs Stable-Dose Conventional Synthetic Disease-Modifying Antirheumatic Drugs on Disease Flares in Patients With Rheumatoid Arthritis in Remission: The ARCTIC REWIND Randomized Clinical Trial.
Lillegraven S; Paulshus Sundlisæter N; Aga AB; Sexton J; Olsen IC; Fremstad H; Spada C; Madland TM; Høili CA; Bakland G; Lexberg Å; Hansen IJW; Hansen IM; Haukeland H; Ljoså MA; Moholt E; Uhlig T; Solomon DH; van der Heijde D; Kvien TK; Haavardsholm EA
JAMA; 2021 May; 325(17):1755-1764. PubMed ID: 33944875
[TBL] [Abstract][Full Text] [Related]
9. Predictors of new bone erosion in rheumatoid arthritis patients receiving conventional synthetic disease-modifying antirheumatic drugs: Analysis of data from the DRIVE and DESIRABLE studies.
Takeuchi T; Soen S; Ishiguro N; Yamanaka H; Tanaka S; Kobayashi M; Okubo N; Nitta T; Tanaka Y
Mod Rheumatol; 2021 Jan; 31(1):34-41. PubMed ID: 31826682
[TBL] [Abstract][Full Text] [Related]
10. Abatacept used in combination with non-methotrexate disease-modifying antirheumatic drugs: a descriptive analysis of data from interventional trials and the real-world setting.
Alten R; Burkhardt H; Feist E; Krüger K; Rech J; Rubbert-Roth A; Voll RE; Elbez Y; Rauch C
Arthritis Res Ther; 2018 Jan; 20(1):1. PubMed ID: 29329602
[TBL] [Abstract][Full Text] [Related]
11. Repair of Bone Erosion in Rheumatoid Arthritis by Denosumab: A High-Resolution Peripheral Quantitative Computed Tomography Study.
Yue J; Griffith JF; Xiao F; Shi L; Wang D; Shen J; Wong P; Li EK; Li M; Li TK; Zhu TY; Hung VW; Qin L; Tam LS
Arthritis Care Res (Hoboken); 2017 Aug; 69(8):1156-1163. PubMed ID: 27768831
[TBL] [Abstract][Full Text] [Related]
12. Effectiveness and safety of 99Tc-methylene diphosphonate as a disease-modifying anti-rheumatic drug (DMARD) in combination with conventional synthetic (cs) DMARDs in the treatment of rheumatoid arthritis: A systematic review and meta-analysis of 34 randomized controlled trials.
Deng G; Chen X; Shao L; Wu Q; Wang S
Heliyon; 2023 Nov; 9(11):e21691. PubMed ID: 37942155
[TBL] [Abstract][Full Text] [Related]
13. Effectiveness of TOcilizumab in comparison to Prednisone In Rheumatoid Arthritis patients with insufficient response to disease-modifying antirheumatic drugs (TOPIRA): study protocol for a pragmatic trial.
van der Leeuw MS; Welsing PMJ; de Hair MJH; Jacobs JWG; Marijnissen ACA; Linn-Rasker SP; Fodili F; Bos R; Tekstra J; van Laar JM
Trials; 2020 Apr; 21(1):313. PubMed ID: 32248829
[TBL] [Abstract][Full Text] [Related]
14. Circulating miR-99b-5p as a novel predictor of erosion progression on high-resolution peripheral quantitative computed tomography in early rheumatoid arthritis: A prospective cohort study.
Yue J; Lau TCK; Griffith JF; Xu J; Xiao F; Shi L; Wang D; Wong PCH; Li EK; Tam LP; Li M; Li TK; Mak WY; Hung V; Qin L; Tam LS
Int J Rheum Dis; 2019 Sep; 22(9):1724-1733. PubMed ID: 31273939
[TBL] [Abstract][Full Text] [Related]
15. Comparative effectiveness of treatment with the first TNF antagonist in monotherapy, the first TNF antagonist plus one conventional synthetic disease-modifying antirheumatic drug, and the first TNF antagonist plus two or more conventional synthetic disease-modifying antirheumatic drugs in patients with rheumatoid arthritis.
Hernández-Cruz B; Márquez-Saavedra E; Caliz-Caliz R; Navarro-Sarabia F
Arthritis Res Ther; 2016 Nov; 18(1):259. PubMed ID: 27821150
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of denosumab with regard to bone destruction in prognostic subgroups of Japanese rheumatoid arthritis patients from the phase II DRIVE study.
Ishiguro N; Tanaka Y; Yamanaka H; Yoneda T; Ohira T; Okubo N; Genant HK; van der Heijde D; Takeuchi T
Rheumatology (Oxford); 2019 Jun; 58(6):997-1005. PubMed ID: 30602032
[TBL] [Abstract][Full Text] [Related]
17. Effect of denosumab on Japanese patients with rheumatoid arthritis: a dose-response study of AMG 162 (Denosumab) in patients with RheumatoId arthritis on methotrexate to Validate inhibitory effect on bone Erosion (DRIVE)-a 12-month, multicentre, randomised, double-blind, placebo-controlled, phase II clinical trial.
Takeuchi T; Tanaka Y; Ishiguro N; Yamanaka H; Yoneda T; Ohira T; Okubo N; Genant HK; van der Heijde D
Ann Rheum Dis; 2016 Jun; 75(6):983-90. PubMed ID: 26585988
[TBL] [Abstract][Full Text] [Related]
18. Micro-structural bone changes in early rheumatoid arthritis persist over 1-year despite use of disease modifying anti-rheumatic drug therapy.
Feehan LM; Li LL; McKay HA
BMC Musculoskelet Disord; 2017 Dec; 18(1):521. PubMed ID: 29228959
[TBL] [Abstract][Full Text] [Related]
19. Effect of treat-to-target strategies on bone erosion progression in early rheumatoid arthritis: An HR-pQCT study.
Yue J; Griffith JF; Xu J; Xiao F; Shi L; Wang D; Wong PCH; Li EK; Li M; Li TK; Mak WY; Zhu TY; Hung VW; Qin L; Tam LS
Semin Arthritis Rheum; 2018 Dec; 48(3):374-383. PubMed ID: 29858113
[TBL] [Abstract][Full Text] [Related]
20. Safety of abatacept compared with other biologic and conventional synthetic disease-modifying antirheumatic drugs in patients with rheumatoid arthritis: data from an observational study.
Ozen G; Pedro S; Schumacher R; Simon TA; Michaud K
Arthritis Res Ther; 2019 Jun; 21(1):141. PubMed ID: 31174592
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
